| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b29ba1a7f2e238a79002c95123eab8a3 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2054 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-64 |
| filingDate |
2008-07-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8b6d7d2aa0396c2c135fd4b2b621a7df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0772fea1e9a7bc0c1dba22b11b777d98
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ca26e7b5766f7c71fe7bd66b62cdf31 |
| publicationDate |
2010-11-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-2090299-A3 |
| titleOfInvention |
Extended Release Gliclazide Formulations |
| abstract |
The present invention relates to an extended release (XL) pharmaceutical tablet composition for oral administration and methods of its manufacture. More particularly, the present invention relates to an extended release gliclazide formulation which does not increase the blood glucose level in human patients. |
| priorityDate |
2007-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |